Clinical trials
Recurrent clinical trials
Below are recruiting recurrent clinical trials, each written for real people, not researchers. We’re tracking 1,424 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06228599Recruiting
Targeted therapy for pancreatic cancer with high risk of return
This trial tests if personalized medicines, chosen based on the genetic profile of your tumor, can help prevent pancreatic cancer from coming back after surgery. It is for people who have had their pancreatic tumor removed but have features that suggest a higher chance of recurrence.
Milwaukee, WisconsinAges 18 years+ - NCT06228937Recruiting
Gut bacteria and lymphedema with repeated infections
This study looks at the bacteria in your gut and how they relate to lymphedema (swelling) and repeated skin infections in the affected limb. It compares people who have many infections with those who have none, to better understand why some get infections and others don't.
RomeAges 18–85 - NCT06229340RecruitingPhase 2
Two drug combinations for advanced cancer with RAS mutations
This trial tests two different treatment combinations (leflunomide alone or with MEK inhibitor and hydroxychloroquine) in people with advanced cancer that has a RAS mutation and has not responded to at least two prior therapies.
Saint PetersburgAges 18–85 - NCT06232122Recruiting
New PET scans to detect ovarian cancer recurrence
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
Taoyuan CityAges 30–80 - NCT06236568Recruiting
Liver transplant study for liver cancer patients
This study tests a special way to preserve donated livers before transplant to see if it reduces the chance of liver cancer coming back after surgery.
Modena, MOAges 18 years+ - NCT06237218Recruiting
Occupational therapy to prevent falls in older adults with dementia
This program tests whether a special type of home-based occupational therapy (called COTID) can help older adults with dementia avoid falling again after a fall that sent them to the hospital. It compares this new approach to usual occupational therapy care.
LimogesAges 75 years+ - NCT06241755RecruitingPhase 3
BCG to prevent bladder cancer return after surgery
This study tests if BCG therapy can prevent bladder cancer from coming back after surgery. It's for people with early-stage bladder cancer that hasn't spread into the muscle layer.
Guangzhou, GuangdongAges 18–75 - NCT06253000Recruiting
Heat vs. Freezing for the Back of the Heart
This trial tests two ways to treat the back wall of the heart's left chamber in people with stubborn atrial fibrillation. It compares radiofrequency (heat) and cryoablation (freezing) to see which is safer and works better.
MoscowAges 18–80 - NCT06258109Recruiting
Pregnancy and stroke risk after artery dissection
This study looks at women who had a cervical artery dissection (a tear in a neck artery) and later became pregnant. It wants to see if pregnancy raises the risk of another dissection or stroke.
Salt Lake City, UtahAges 18 years+ - NCT06258642Recruiting
Irinotecan liposome plus anlotinib for SCLC after first chemo
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06264388RecruitingPhase 2
Gene therapy plus oral drug for recurrent brain tumors
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
Miami, FloridaAges 18–75 - NCT06266338RecruitingPhase 2
Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Dallas, TexasAges 18 years+ - NCT06271941Recruiting
Reducing polyp return after large colon polyp removal
This trial is testing a standard way to remove large polyps from the colon and checking if it helps prevent them from coming back. It's for people who have a large non-cancerous polyp that needs to be taken out during a colonoscopy.
Montreal, QuebecAges 18 years+ - NCT06275919RecruitingPhase 2
Regorafenib for recurring meningioma
This trial tests a pill called regorafenib for people whose meningioma (a brain tumor) has come back and cannot be treated with surgery or radiation. The goal is to see if regorafenib can help stop the tumor from growing further.
Meldola, Forlì-CesenaAges 18 years+ - NCT06279364RecruitingPhase 3
Testing SKB264 vs standard chemo for advanced triple-negative breast cancer
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06279442Recruiting
Study of adrenocortical cancer in a Brazilian group
This study looks at patients with adrenocortical carcinoma, a rare type of adrenal gland cancer, to learn more about the disease and how it affects people in Brazil. You may join if you were diagnosed or had a recurrence in 2000 or later and have had a clinic visit at the participating hospital.
Fortaleza, CearáAges 18 years+ - NCT06292689RecruitingPhase 2
Cardunolizumab for advanced vulvar or vaginal cancer
This study is testing a new drug called cardunolizumab for people with advanced vulvar or vaginal cancer that has come back or spread. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT06301945Recruiting
AI tool for thymus tumors
This study is using an artificial intelligence tool to help doctors better predict how thymus tumors (thymoma and thymic carcinoma) will behave. It may help guide decisions about treatment and follow-up.
Rotterdam, South HollandAges Any age - NCT06305299RecruitingPhase 1
CAR-T cell therapy for ovarian cancer
This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.
Chapel Hill, North CarolinaAges 18 years+ - NCT06320405RecruitingPhase 1/Phase 2
Combination therapy for advanced solid tumors
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
Portland, OregonAges 18 years+ - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT07694674Recruiting
Comparing Biologic Drugs to Prevent Crohn's Return After Surgery
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07678684RecruitingPhase 2
Study of HF1K16 plus bevacizumab for recurrent glioma
This trial tests a new combination of two drugs, HF1K16 and bevacizumab, for people whose glioma has come back or grown after prior treatment. It aims to see if this combination can help when standard options are no longer working or tolerable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Tucson, ArizonaAges 18 years+
Hear when a new Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent?
- Yes. Clin2 currently lists 1,424 recruiting recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.